Last $27.28 USD
Change Today -0.25 / -0.91%
Volume 279.9K
As of 8:10 PM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

spectranetics corp (SPNC) Snapshot

Open
$27.42
Previous Close
$27.53
Day High
$27.66
Day Low
$27.05
52 Week High
03/21/14 - $31.94
52 Week Low
09/24/13 - $15.82
Market Cap
1.1B
Average Volume 10 Days
420.6K
EPS TTM
$-0.18
Shares Outstanding
41.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SPECTRANETICS CORP (SPNC)

Related News

No related news articles were found.

spectranetics corp (SPNC) Related Businessweek News

No Related Businessweek News Found

spectranetics corp (SPNC) Details

The Spectranetics Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Its products are used to treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. The company's vascular intervention product line includes peripheral atherectomy, a range of laser catheters for ablation of blockages in arteries above and below the knee; crossing solutions, which support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions; and coronary atherectomy and thrombectomy, which are aspiration and cardiac laser catheters for the treatment of blockages in the heart. Its primary vascular intervention products include the Turbo Elite and Turbo-Tandem laser catheters and the TAPAS drug delivery catheters for peripheral atherectomy; crossing catheters, such as the Quick-Cross, Quick-Cross Select, and Quick-Cross Extreme; the ELCA Laser Ablation Catheter for coronary atherectomy; and QuickCat aspiration catheter for thrombus management. The company's lead management product line comprises excimer laser sheaths, non-laser sheaths, and cardiac lead management accessories, such as Spectranetics Laser Sheath, GlideLight, and Lead Locking Device for the removal of pacemaker and defibrillator cardiac leads. It sells its products in the United States, Canada, Europe, the Middle East, the Asia Pacific, Latin America, and Puerto Rico. The Spectranetics Corporation was founded in 1984 and is headquartered in Colorado Springs, Colorado.

575 Employees
Last Reported Date: 09/5/14
Founded in 1984

spectranetics corp (SPNC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $596.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $316.2K
Chief Operating Officer
Total Annual Compensation: $265.6K
Senior Vice President of Lead Management Sale...
Total Annual Compensation: $265.7K
Senior Vice President and General Counsel
Total Annual Compensation: $238.9K
Compensation as of Fiscal Year 2013.

spectranetics corp (SPNC) Key Developments

The Spectranetics Corporation Announces Results of EXCITE ISR clinical trial

The Spectranetics Corporation announced findings from the EXCITE ISR clinical trial proving that the company's laser atherectomy devices, used with PTA, or balloon angioplasty, for the treatment of in-stent restenosis, or ISR, are clinically superior to PTA alone in both safety and efficacy, triggering a new standard in cardiovascular care. Critical data findings include: 93.5% procedural success rate using Turbo-Tandem with PTA vs. 82.7% with PTA alone (p = 0.01); Primary safety endpoint, MAE rates at 30 days 5.8% vs. 20.5% with PTA alone (p < 0.001); Primary efficacy endpoint, 73.5% freedom from target lesion revascularization at 6 months vs. 51.8% with PTA alone (p < 0.005); Excimer laser atherectomy with adjunctive PTA was associated with a 52% reduction in TLR (Hazard Ratio 0.48; 95% CI 0.31 - 0.74); Dissection rate of 7.7% vs. 17.2% with PTA alone (p = 0.03); Bailout stenting 4.1% vs. 11.1% with PTA alone (p = 0.05); and There was no procedurally related stent damage observed in either cohort. Notably, the study's average lesion length was approximately 20 cm as compared to various stent IDE studies with average lesion lengths of 4 to 6 cm. Additionally, a high number of complex or advanced disease-state patients were enrolled in the trial, indicative of success in treating many types of ISR lesions, including the most complex cases. The EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal (arteries above the knee) In-Stent Restenosis (EXCITE ISR) is the first large multi-center, prospective randomized trial ever conducted for the treatment of FemPop ISR. The EXCITE ISR trial was designed to enroll a maximum of 318 subjects at up to 40 sites, randomized 2:1 treatment to control with predetermined statistical analyses at 200, 250 and 300 enrolled patients. Earlier this year, Spectranetics announced success of the trial based on achieving highly significant statistical superiority in both safety and efficacy among 250 patients. The treatment arm is laser atherectomy combined with PTA and the control arm is PTA alone. The primary efficacy endpoint is freedom from TLR through six months. The primary safety endpoint is freedom from major adverse events at 30 days. MAEs include all-cause mortality, major amputation in the target limb, or TLR.

The Spectranetics Corporation Presents at CRT Capital Group's 2nd Annual Investor Conference, Sep-16-2014

The Spectranetics Corporation Presents at CRT Capital Group's 2nd Annual Investor Conference, Sep-16-2014 . Venue: Delamar Hotel, Greenwich, Connecticut, United States.

The Spectranetics Corporation Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 11:30 AM

The Spectranetics Corporation Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 11:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Scott William Drake, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPNC:US $27.28 USD -0.25

SPNC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ABIOMED Inc $24.94 USD -0.05
Cardiovascular Systems Inc $25.88 USD -1.06
CryoLife Inc $10.14 USD -0.03
Endologix Inc $13.55 USD -0.24
Vascular Solutions Inc $23.64 USD +0.48
View Industry Companies
 

Industry Analysis

SPNC

Industry Average

Valuation SPNC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.0x
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRANETICS CORP, please visit www.spectranetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.